Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS mRNA Vaccine in KRAS-mutant Malignancies
NCT07004244Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in solid tumor (2 cohorts), sponsored by Sichuan University. Primary endpoints: Adverse events up to 12 months and Immunogenicity of the mRNA vaccine up to 7 months. Started Jun 2025; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07004244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004244.